JP2016539096A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539096A5 JP2016539096A5 JP2016524116A JP2016524116A JP2016539096A5 JP 2016539096 A5 JP2016539096 A5 JP 2016539096A5 JP 2016524116 A JP2016524116 A JP 2016524116A JP 2016524116 A JP2016524116 A JP 2016524116A JP 2016539096 A5 JP2016539096 A5 JP 2016539096A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- vegf
- composition according
- ctla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892601P | 2013-10-18 | 2013-10-18 | |
| US61/892,601 | 2013-10-18 | ||
| US201361901596P | 2013-11-08 | 2013-11-08 | |
| US61/901,596 | 2013-11-08 | ||
| US201461952923P | 2014-03-14 | 2014-03-14 | |
| US61/952,923 | 2014-03-14 | ||
| US201462055734P | 2014-09-26 | 2014-09-26 | |
| US62/055,734 | 2014-09-26 | ||
| PCT/US2014/061071 WO2015058048A1 (en) | 2013-10-18 | 2014-10-17 | Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539096A JP2016539096A (ja) | 2016-12-15 |
| JP2016539096A5 true JP2016539096A5 (enExample) | 2017-11-09 |
| JP6607850B2 JP6607850B2 (ja) | 2019-11-20 |
Family
ID=51844874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524116A Active JP6607850B2 (ja) | 2013-10-18 | 2014-10-17 | Ｖｅｇｆアンタゴニスト及び抗ｃｔｌａ−４抗体の組み合わせを含む方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9968674B2 (enExample) |
| EP (1) | EP3057990B1 (enExample) |
| JP (1) | JP6607850B2 (enExample) |
| KR (1) | KR102338453B1 (enExample) |
| CN (1) | CN105636986B (enExample) |
| AU (1) | AU2014337135B2 (enExample) |
| CA (1) | CA2926853C (enExample) |
| EA (1) | EA037890B1 (enExample) |
| IL (1) | IL244599B (enExample) |
| MX (1) | MX377714B (enExample) |
| WO (1) | WO2015058048A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101482483B1 (ko) | 2006-04-07 | 2015-01-15 | 에르피오 세러퓨틱스 인코포레이티드 | 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도 |
| CA2850830A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| EP3800191B1 (en) | 2014-03-17 | 2025-08-20 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| JP7095994B2 (ja) | 2015-03-02 | 2022-07-05 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法 |
| CA2986765A1 (en) | 2015-05-29 | 2016-12-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| AU2016370821A1 (en) | 2015-12-18 | 2018-07-12 | Biogen Ma Inc. | Bispecific antibody platform |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| EP3433275A1 (en) | 2016-03-24 | 2019-01-30 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| SI3471780T1 (sl) * | 2016-06-16 | 2021-03-31 | Adverum Biotechnologies, Inc. | Zdravljenje SDM-ja z uporabo različice AAV2 z afliberceptom |
| US10253094B2 (en) | 2016-07-20 | 2019-04-09 | Aerpio Therapeutics, Inc. | Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| US11168327B2 (en) | 2017-01-31 | 2021-11-09 | Research Development Foundation | STEAP2 inhibitors for the treatment of liver cancers |
| MA50908A (fr) | 2017-11-17 | 2020-09-23 | Amgen Inc | Formulations de protéines de fusion vegfr-fc |
| AU2019214865B2 (en) * | 2018-02-02 | 2025-04-10 | OncoC4, Inc. | Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects |
| EP3746122A4 (en) * | 2018-02-02 | 2021-11-24 | OncoC4, Inc. | SAFER AND MORE EFFECTIVE ANTI-CTLA-4 ANTIBODY SELECTION AND DESIGN PROCESSES FOR CANCER THERAPY |
| US12071476B2 (en) * | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| MX2020012091A (es) | 2018-05-14 | 2021-04-28 | Oncoimmune Inc | Composiciones anti-cd24 y usos de las mismas. |
| US10894824B2 (en) | 2018-09-24 | 2021-01-19 | Aerpio Pharmaceuticals, Inc. | Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF |
| SG11202104373YA (en) * | 2018-10-31 | 2021-05-28 | Bioatla Inc | Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| CN111378044B (zh) * | 2018-12-28 | 2022-07-15 | 长春金赛药业有限责任公司 | 抗体融合蛋白、制备方法及其应用 |
| US20220098279A1 (en) * | 2019-01-30 | 2022-03-31 | Amgen Inc. | Aflibercept attributes and methods of characterizing and modifying thereof |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19802753A1 (de) * | 1998-01-26 | 1999-07-29 | Merck Patent Gmbh | Coreaktive Trägermaterialien zur Heterogenisierung von Katalysatoren, Cokatalysatoren und Liganden |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7303746B2 (en) * | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CN102766210B (zh) | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| CA2586844A1 (en) * | 2004-11-04 | 2006-05-11 | Pfizer Products Inc. | Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
| WO2007113648A2 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| US8216571B2 (en) * | 2007-10-22 | 2012-07-10 | Schering Corporation | Fully human anti-VEGF antibodies and methods of using |
| US8263073B2 (en) | 2008-02-04 | 2012-09-11 | Medarex, Inc. | Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
-
2014
- 2014-10-17 MX MX2016004736A patent/MX377714B/es active IP Right Grant
- 2014-10-17 CA CA2926853A patent/CA2926853C/en active Active
- 2014-10-17 AU AU2014337135A patent/AU2014337135B2/en active Active
- 2014-10-17 KR KR1020167013164A patent/KR102338453B1/ko active Active
- 2014-10-17 US US15/026,460 patent/US9968674B2/en active Active
- 2014-10-17 EP EP14792686.9A patent/EP3057990B1/en active Active
- 2014-10-17 CN CN201480054902.1A patent/CN105636986B/zh active Active
- 2014-10-17 WO PCT/US2014/061071 patent/WO2015058048A1/en not_active Ceased
- 2014-10-17 EA EA201690633A patent/EA037890B1/ru unknown
- 2014-10-17 JP JP2016524116A patent/JP6607850B2/ja active Active
-
2016
- 2016-03-15 IL IL24459916A patent/IL244599B/en active IP Right Grant
-
2018
- 2018-04-23 US US15/959,595 patent/US10532096B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7170691B2 (ja) | 抗ｌａｇ３抗体およびその使用 | |
| TWI707871B (zh) | 抗lag3抗體 | |
| US20240190999A1 (en) | Multispecific proteins | |
| US9822181B2 (en) | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof | |
| JP2020115876A (ja) | Ｐｄ−ｌ１に対するヒト抗体 | |
| JP7162535B2 (ja) | 抗ｇｉｔｒ抗体およびその使用 | |
| JP2023062184A (ja) | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍－関連抗原に結合するタンパク質 | |
| RS59688B1 (sr) | 5-bromo-2,6-di-(1h-pirazol-1-il)pirimidin-4-amin za upotrebu pri lečenju raka | |
| JP2023145487A (ja) | 抗ｔｉｍ－３抗体のための投与レジメンおよびその使用 | |
| JP2016527286A5 (enExample) | ||
| JP2018501197A5 (enExample) | ||
| JP7754506B2 (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| WO2015037005A1 (en) | Anti-vstm5 antibodies and the use thereof in therapy and diagnosis | |
| CN106068275A (zh) | 抗pd‑1的人抗体 | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| JP2015529641A5 (enExample) | ||
| JP2014534237A5 (enExample) | ||
| RU2012139829A (ru) | АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8 | |
| JP2015506961A5 (enExample) | ||
| JP2020530770A5 (enExample) | ||
| CN110381974A (zh) | 基于csf1r的嵌合蛋白 | |
| CN108026159B9 (zh) | Btla融合蛋白激动剂及其用途 | |
| JP2024509501A (ja) | 新規活性を持つｈｈｌａ２結合剤 | |
| CN113454123A (zh) | Lilrb3结合分子及其用途 | |
| TW202328196A (zh) | 使用vista抗原結合分子的癌症之治療及預防 |